Drug intelligence / Profile preview

Prospidelong

Development stage: Phase 3
Lead developer: UNITEHPROM
Modality: Small Molecules
Administration: Topical, Intraperitoneal

Overview

Prospidium chloride (Prospidelong) is an anticancer drug formulated as a powder for preparation of a gel for topical use. It is specifically designed for intraperitoneal administration in patients with disseminated gastric cancer. The drug is administered at a dose of 4000 mg (equivalent to 2000 mg of prospidium chloride).

Brand names: Prospidelong

Beyond the preview

Go deeper on Prospidelong.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prospidelong.

Explore the full profile